{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T18:01:28Z","timestamp":1790272888796,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Patient"],"DOI":"10.1007\/s40271-026-00842-1","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:10:05Z","timestamp":1790269805000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Experiences with Efanesoctocog Alfa: Exit Interviews with Caregivers of Previously Treated XTEND-Kids Phase III Trial Patients with Haemophilia A"],"prefix":"10.1007","author":[{"given":"Lynn","family":"Malec","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Carcao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Mathias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nana","family":"Kragh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Dumont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Bystrick\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sriya","family":"Gunawardena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Kosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2294-9519","authenticated-orcid":false,"given":"Dana","family":"DiBenedetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"key":"842_CR1","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/s0140-6736(15)01123-x","volume":"388","author":"F Peyvandi","year":"2016","unstructured":"Peyvandi F, Garagiola I, Young G. The past and future of haemophilia: diagnosis, treatments, and its complications. Lancet. 2016;388:187\u201397. https:\/\/doi.org\/10.1016\/s0140-6736(15)01123-x.","journal-title":"Lancet"},{"key":"842_CR2","unstructured":"World Federation of Hemophilia. World Federation of Hemophilia report on the annual global survey 2022. 2023."},{"key":"842_CR3","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/hae.14455","volume":"28","author":"J Astermark","year":"2022","unstructured":"Astermark J, Hermans C, Ezzalfani M, Aball\u00e9a S, Santagostino E, Hakimi Z, et al. rFIXFc prophylaxis improves pain and levels of physical activity in haemophilia B: post hoc analysis of B-LONG using haemophilia-specific quality of life questionnaires. Haemophilia. 2022;28:18\u201326. https:\/\/doi.org\/10.1111\/hae.14455.","journal-title":"Haemophilia"},{"key":"842_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00278-x","volume":"7","author":"E Berntorp","year":"2021","unstructured":"Berntorp E, Fischer K, Hart DP, Mancuso ME, Stephensen D, Shapiro AD, et al. Haemophilia. Nat Rev Dis Primers. 2021;7:45. https:\/\/doi.org\/10.1038\/s41572-021-00278-x.","journal-title":"Nat Rev Dis Primers"},{"key":"842_CR5","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1111\/jth.15444","volume":"19","author":"R Gualtierotti","year":"2021","unstructured":"Gualtierotti R, Solimeno LP, Peyvandi F. Hemophilic arthropathy: current knowledge and future perspectives. J Thromb Haemost. 2021;19:2112\u201321. https:\/\/doi.org\/10.1111\/jth.15444.","journal-title":"J Thromb Haemost"},{"key":"842_CR6","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1111\/hae.14866","volume":"29","author":"L Malec","year":"2023","unstructured":"Malec L, Matino D. Targeting higher factor VIII levels for prophylaxis in haemophilia A: a narrative review. Haemophilia. 2023;29:1419\u201329. https:\/\/doi.org\/10.1111\/hae.14866.","journal-title":"Haemophilia"},{"issue":"Suppl 6","key":"842_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/hae.14046","volume":"26","author":"A Srivastava","year":"2020","unstructured":"Srivastava A, Santagostino E, Dougall A, Kitchen S, Sutherland M, Pipe SW, et al. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia. 2020;26(Suppl 6):1\u2013158. https:\/\/doi.org\/10.1111\/hae.14046.","journal-title":"Haemophilia"},{"key":"842_CR8","unstructured":"US Food and Drug Administration. ROCTAVIAN (valoctocogene roxaparvovec-rvox) prescribing information. 2023."},{"key":"842_CR9","unstructured":"Food and Drug Administration. ROCTAVIAN. 2025."},{"key":"842_CR10","unstructured":"European Commission. COMMISSION IMPLEMENTING DECISION of 30.4.2026 withdrawing, at the holder's request, the conditional marketing authorisation granted by Decision C(2022) 6194 final for \"Roctavian - valoctocogene roxaparvovec\", an orphan medicinal product for human use. 2026."},{"key":"842_CR11","unstructured":"BioMarin. BioMarin Voluntarily Withdraws ROCTAVIAN\u00ae (valoctocogene roxaparvovec-rvox) from the Market\u202f2026."},{"key":"842_CR12","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.3324\/haematol.2019.241554","volume":"106","author":"A Tiede","year":"2021","unstructured":"Tiede A, Abdul Karim F, Jim\u00e9nez-Yuste V, Klamroth R, Lejniece S, Suzuki T, et al. Factor VIII activity and bleeding risk during prophylaxis for severe hemophilia A: a population pharmacokinetic model. Haematologica. 2021;106:1902\u20139. https:\/\/doi.org\/10.3324\/haematol.2019.241554.","journal-title":"Haematologica"},{"key":"842_CR13","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1182\/blood-2015-01-528414","volume":"125","author":"J Oldenburg","year":"2015","unstructured":"Oldenburg J. Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens. Blood. 2015;125:2038\u201344. https:\/\/doi.org\/10.1182\/blood-2015-01-528414.","journal-title":"Blood"},{"key":"842_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-021-00760-4","volume":"28","author":"D Okaygoun","year":"2021","unstructured":"Okaygoun D, Oliveira DD, Soman S, Williams R. Advances in the management of haemophilia: emerging treatments and their mechanisms. J Biomed Sci. 2021;28:64. https:\/\/doi.org\/10.1186\/s12929-021-00760-4.","journal-title":"J Biomed Sci"},{"key":"842_CR15","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1182\/bloodadvances.2021006119","volume":"6","author":"T Lissitchkov","year":"2022","unstructured":"Lissitchkov T, Willemze A, Katragadda S, Rice K, Poloskey S, Benson C. Efanesoctocog alfa for hemophilia A: results from a phase 1 repeat-dose study. Blood Adv. 2022;6:1089\u201394. https:\/\/doi.org\/10.1182\/bloodadvances.2021006119.","journal-title":"Blood Adv"},{"key":"842_CR16","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1182\/blood.2019001292","volume":"135","author":"E Seth Chhabra","year":"2020","unstructured":"Seth Chhabra E, Liu T, Kulman J, Patarroyo-White S, Yang B, Lu Q, et al. BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice. Blood. 2020;135:1484\u201396. https:\/\/doi.org\/10.1182\/blood.2019001292.","journal-title":"Blood"},{"key":"842_CR17","unstructured":"US Food and Drug Administration. ALTUVIIIO (efanesoctocog alfa) prescribing information. 2023."},{"key":"842_CR18","unstructured":"European Medicines Agency. Altuvoct: EPAR\u2014Product information. 2024."},{"key":"842_CR19","unstructured":"clinicaltrials.gov. NCT04161495, A Phase 3 open-label interventional study of intravenous recombinant coagulation factor VIII Fc-von Willebrand factor-XTEN fusion protein, efanesoctocog alfa (BIVV001), in patients with severe hemophilia A (XTEND-1). 2025."},{"key":"842_CR20","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1056\/NEJMoa2209226","volume":"388","author":"A von Drygalski","year":"2023","unstructured":"von Drygalski A, Chowdary P, Kulkarni R, Susen S, Konkle BA, Oldenburg J, et al. Efanesoctocog alfa prophylaxis for patients with severe hemophilia A. N Engl J Med. 2023;388:310\u20138. https:\/\/doi.org\/10.1056\/NEJMoa2209226.","journal-title":"N Engl J Med"},{"key":"842_CR21","unstructured":"clinicaltrials.gov. NCT04759131, Safety, efficacy and PK of BIVV001 in pediatric patients with hemophilia A (XTEND-Kids). 2025."},{"key":"842_CR22","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa2312611","volume":"391","author":"L Malec","year":"2024","unstructured":"Malec L, Peyvandi F, Chan AKC, K\u00f6nigs C, Zulfikar B, Yuan H, et al. Efanesoctocog alfa prophylaxis for children with severe hemophilia A. N Engl J Med. 2024;391:235\u201346. https:\/\/doi.org\/10.1056\/NEJMoa2312611.","journal-title":"N Engl J Med"},{"key":"842_CR23","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s40271-024-00726-2","volume":"18","author":"N Williamson","year":"2025","unstructured":"Williamson N, Howse C, Hodson N, Stein J, Arbuckle R. Qualitative in-trial interviews: methods, challenges, and best practice. Patient. 2025;18:199\u2013209. https:\/\/doi.org\/10.1007\/s40271-024-00726-2.","journal-title":"Patient"},{"key":"842_CR24","unstructured":"US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Patient-focused drug development: methods to identify what is important to patients. Guidance for industry, Food and Drug Administration staff, and other stakeholders. 2022."},{"key":"842_CR25","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/j.clinthera.2024.09.010","volume":"46","author":"D DiBenedetti","year":"2024","unstructured":"DiBenedetti D, Neme D, Pan-Petesch B, Willemze A, Wynn T, Kragh N, et al. Patient experience with efanesoctocog alfa for severe hemophilia A: results from the XTEND-1 phase 3 clinical study exit interviews. Clin Ther. 2024;46:1016\u201323. https:\/\/doi.org\/10.1016\/j.clinthera.2024.09.010.","journal-title":"Clin Ther"},{"key":"842_CR26","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1007\/s11136-016-1256-z","volume":"25","author":"ZS Patel","year":"2016","unstructured":"Patel ZS, Jensen SE, Lai JS. Considerations for conducting qualitative research with pediatric patients for the purpose of PRO development. Qual Life Res. 2016;25:2193\u20139. https:\/\/doi.org\/10.1007\/s11136-016-1256-z.","journal-title":"Qual Life Res"},{"key":"842_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s41687-021-00371-5","volume":"5","author":"A Fry","year":"2021","unstructured":"Fry A, Mitchell SA, Wiener L. Considerations for conducting and reporting digitally supported cognitive interviews with children and adults. J Patient Rep Outcomes. 2021;5:131. https:\/\/doi.org\/10.1186\/s41687-021-00371-5.","journal-title":"J Patient Rep Outcomes"},{"issue":"Suppl 1","key":"842_CR28","doi-asserted-by":"publisher","first-page":"PO203","DOI":"10.1111\/hae.14715","volume":"29","author":"A Wilson","year":"2023","unstructured":"Wilson A, Kragh N, DiBenedetti D, Pan-Petesch B, Wynn T, Neme D, et al. Patient experience with efanesoctocog alfa: results from the XTEND-1 phase 3 clinical trial exit interviews in patients with severe haemophilia A. Haemophilia. 2023;29(Suppl 1):PO203. https:\/\/doi.org\/10.1111\/hae.14715. (Poster presented at the 75th Bleeding Disorders Conference (BDC); August 17, 2023 Baltimore, MD).","journal-title":"Haemophilia"},{"key":"842_CR29","unstructured":"US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Patient-focused drug development: collecting comprehensive and representative input. Guidance for industry, Food and Drug Administration staff, and other stakeholders. 2020."},{"issue":"Suppl 2","key":"842_CR30","doi-asserted-by":"publisher","first-page":"s4","DOI":"10.2450\/2008.0030-08","volume":"6","author":"A Coppola","year":"2008","unstructured":"Coppola A, Di Capua M, De Simone C. Primary prophylaxis in children with haemophilia. Blood Transfus. 2008;6(Suppl 2):s4\u201311. https:\/\/doi.org\/10.2450\/2008.0030-08.","journal-title":"Blood Transfus"},{"key":"842_CR31","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1111\/j.1538-7836.2011.04214.x","volume":"9","author":"A Gringeri","year":"2011","unstructured":"Gringeri A, Lundin B, von Mackensen S, Mantovani L, Mannucci PM. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT study). J Thromb Haemost. 2011;9:700\u201310. https:\/\/doi.org\/10.1111\/j.1538-7836.2011.04214.x.","journal-title":"J Thromb Haemost"},{"key":"842_CR32","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1111\/j.1365-2796.1994.tb00815.x","volume":"236","author":"LM Aledort","year":"1994","unstructured":"Aledort LM, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group. J Intern Med. 1994;236:391\u20139. https:\/\/doi.org\/10.1111\/j.1365-2796.1994.tb00815.x.","journal-title":"J Intern Med"},{"key":"842_CR33","first-page":"691","volume":"73","author":"E Berntorp","year":"1995","unstructured":"Berntorp E, Boulyjenkov V, Brettler D, Chandy M, Jones P, Lee C, et al. Modern treatment of haemophilia. Bull World Health Organ. 1995;73:691\u2013701.","journal-title":"Bull World Health Organ"},{"key":"842_CR34","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/j.1365-2796.1992.tb00546.x","volume":"232","author":"IM Nilsson","year":"1992","unstructured":"Nilsson IM, Berntorp E, L\u00f6fqvist T, Pettersson H. Twenty-five years\u2019 experience of prophylactic treatment in severe haemophilia A and B. J Intern Med. 1992;232:25\u201332. https:\/\/doi.org\/10.1111\/j.1365-2796.1992.tb00546.x.","journal-title":"J Intern Med"},{"key":"842_CR35","doi-asserted-by":"publisher","first-page":"3073","DOI":"10.1182\/blood-2015-10-675140","volume":"127","author":"MA Mazepa","year":"2016","unstructured":"Mazepa MA, Monahan PE, Baker JR, Riske BK, Soucie JM. Men with severe hemophilia in the United States: birth cohort analysis of a large national database. Blood. 2016;127:3073\u201381. https:\/\/doi.org\/10.1182\/blood-2015-10-675140.","journal-title":"Blood"},{"key":"842_CR36","doi-asserted-by":"publisher","unstructured":"DiBenedetti DB, Brown TM, Romano C, Ervin C, Lewis S, Fehnel SE. Conducting patient interviews within a clinical trial setting. RTI Press Publication 2018; No. OP-0054-1808. https:\/\/doi.org\/10.3768\/rtipress.2018.op.0054.1808.","DOI":"10.3768\/rtipress.2018.op.0054.1808"}],"container-title":["The Patient - Patient-Centered Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-026-00842-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40271-026-00842-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-026-00842-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:10:15Z","timestamp":1790269815000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40271-026-00842-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,24]]},"references-count":36,"alternative-id":["842"],"URL":"https:\/\/doi.org\/10.1007\/s40271-026-00842-1","relation":{},"ISSN":["1178-1653","1178-1661"],"issn-type":[{"value":"1178-1653","type":"print"},{"value":"1178-1661","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,24]]},"assertion":[{"value":"27 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"L.M. reports receiving research support from Sanofi, and CSL Behring, and honoraria for speaking\/participating in advisory boards from Sanofi, Sobi, CSL Behring, Takeda, Novo Nordisk, BioMarin, Genentech, and Pfizer. M.C. reports receiving research support from Novo Nordisk, Pfizer, Roche, and Sanofi and honoraria for speaking\/participating in advisory boards from Novo Nordisk, Pfizer, Roche, and Sanofi. M.M. has received research and travel support from Sanofi and Sobi, and consultancy fees from Sobi. N.K. is an employee of Sobi and may have stock\/stock options. J.D. is an employee of Sanofi and may hold shares and\/or stock options in the company. L.B. is an employee of Sobi and may have stock\/stock options. S.G. is an employee of Sanofi and may hold shares and\/or stock options in the company. A.W. is a prior employee of Sanofi and may have stock\/options. K.K. and D.D. are employees of RTI Health Solutions, an independent non-profit research organisation that received funding from Sanofi to conduct the study. Their compensation is unconnected to this study.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Qualified researchers may request access to patient-level data and related study documents. Patient-level data will be anonymised, and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi\u2019s data-sharing criteria, eligible studies, and process for requesting access can be found at:\n                      \n                      .","order":2,"name":"Ethics","label":"Data Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki. Each of the respective clinical sites in Canada, France, UK, and USA obtained appropriate institutional review board\/ethics committee approvals for the interviews.","order":3,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all caregivers included in the study.","order":4,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"D.D., K.K., and A.W. made substantial contributions to study design. D.D. and K.K. made substantial contributions to the acquisition of data. D.D. and K.K. made substantial contributions to analysis of data. D.D., K.K., N.K., J.D., L.B., L.M., and A.W. made substantial contributions to the interpretation of data. All authors were involved in drafting the work or revising it critically for important intellectual content, and in final approval of the version to be published. All authors have agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.","order":5,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}